Cardiothoracic & vascular anesthesia
The low-dose colchicine in patients after non-CABG cardiac surgery: a randomized controlled trial
Authors' conclusion
A short perioperative course of low-dose colchicine was effective to attenuate the postoperative biomarkers of myocardial injury and inflammation, and to decrease the postoperative syndrome compared with the placebo.
Study context
- Population
- Patients undergoing non-CABG cardiac surgery with CPB11 excluded
- Participants
- 132 patients
- Comparison
- Low-dose colchicine vs placebo
- Colchicinen = 59
- Placebon = 62reference
- Primary endpoint
- Cardiac troponin T (cTnT) level
- Follow-up
- Postoperative 48 h
Methodological detailsplacebo-controlled
- Placebo-controlled
Primary result
As reported in the abstract
cTnT
P < 0.01
Secondary outcomes
Cardiac troponin I · postoperative 48 h
P = 0.02
CK-MB · postoperative 48 h
P < 0.01
Interleukin-6 · postoperative 48 h
P = 0.048
Safety
Post-pericardiotomy syndrome
P < 0.01
| Outcome | Colchicine | Placebo | P value |
|---|---|---|---|
| Diarrhoea | 9.23% | 0 | P = 0.01 |
- Post-pericardiotomy syndrome: safety set: Colchicine n = 65, Placebo n = 62
Other adverse events
- No significant difference between the two groups
Original publication
The low-dose colchicine in patients after non-CABG cardiac surgery: a randomized controlled trial. Crit Care. Published 7 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →